前言

英文标题：Phase II Study of iza-bren (BL-B01D1) in Combination with Serplulimab in Patients with Small Cell Lung Cancer (SCLC)

中文标题：iza-bren (BL-B01D1) 联合斯鲁利单抗治疗SCLC的II期研究

英文标题：A phase I dose escalation trial of obrixtamig + ezabenlimab in patients (pts) with small cell lung cancer (SCLC) or other neuroendocrine carcinomas (NECs) expressing DLL3

中文标题：Obrixtamig联合Ezabenlimab治疗表达DLL3的SCLC或其他神经内分泌癌（NECs）患者的I期剂量递增试验

英文标题：Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase 3 ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

中文标题：III期ADRIATIC研究中局限期小细胞肺癌（LS-SCLC）患者同步放化疗（cCRT）后接受度伐利尤单抗巩固治疗的后续治疗模式及其对患者预后的影响

英文标题：SNC115 in patients with relapsed/refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC): Safety, pharmacokinetic, and preliminary efficacy results from a phase 1 study

中文标题： SNC115治疗复发/难治性SCLC和大细胞神经内分泌癌（LCNEC）患者：一项I期研究的安全性、药代动力学和初步疗效结果

英文标题：Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 5-year update of the phase 3 CAPSTONE-1 study

中文标题：阿得贝利单抗联合化疗一线治疗广泛期小细胞肺癌（ES-SCLC）：III期CAPSTONE-1研究的5年更新数据

英文标题：Phase 2 Study of First-Line Pumitamig (PD-L1 _ VEGF-A bsAb) Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): Updated Efficacy and Safety Results

中文标题：Pumitamig（PD-L1/VEGF-A双抗）联合化疗一线治疗ES-SCLC的II期研究：更新的疗效和安全性结果

英文标题：Interim Results of a Randomized Phase II Trial of Trilaciclib Combined with Envafolimab, Etoposide, and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

中文标题：曲拉西利联合恩沃利单抗、依托泊苷和卡铂一线治疗ES-SCLC的随机II期试验中期结果

英文标题：ROSETTA Lung-01: A Phase 3, Two-Stage Trial of Pumitamig, a PD-L1 _ VEGF-A Bispecific Antibody, Plus Chemotherapy Versus Atezolizumab + Chemotherapy as First-Line Treatment in Patients With Extensive-Stage Small Cell Lung Cancer

中文标题：ROSETTA Lung-01：一项比较Pumitamig（PD-L1/VEGF-A双特异性抗体）联合化疗与阿替利珠单抗联合化疗一线治疗ES-SCLC的III期、两阶段试验

英文标题：A phase 2/3 trial of a PD-1/VEGF bispecific antibody (PF-08634404) in combination with chemotherapy in first-line for extensive-stage small cell lung cancer (Symbiotic-Lung-04)

中文标题：PD-1/VEGF双特异性抗体（PF-08634404）联合化疗一线治疗ES-SCLC的II/III期试验（Symbiotic-Lung-04）

英文标题：SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC)

中文标题：SEZanne：一项评估ABBV-706联合阿替利珠单抗对比标准治疗（SOC）在初治ES-SCLC患者中的最佳剂量、安全性和疗效的II期随机、开放标签、多中心研究

英文标题：DeLLphi-312 Phase 3 Trial-in-Progress: Tarlatamab With Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide As First-Line (1L) Therapy in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

中文标题：DeLLphi-312 III期进行中试验（TiP）：塔拉妥单抗（Tarlatamab）联合度伐利尤单抗、卡铂和依托泊苷对比度伐利尤单抗、卡铂和依托泊苷一线治疗ES-SCLC

英文标题：Maintenance therapy with adebrelimab plus vunakizumab for ES-SCLC after first-line induction with adebrelimab and chemotherapy: a prospective, single-arm, phase II clinical study

中文标题：阿得贝利单抗联合化疗一线诱导治疗后，采用阿得贝利单抗联合vunakizumab维持治疗ES-SCLC：一项前瞻性、单臂、II期临床研究